Impact of hepatitis B core antibody (anti HBc) seropositivity on interferon/ribavirin treatment response in patients with chronic hepatitis C.
AntiHBc seropositivity among patients with chronic HCV infection is not a rare entity (57.14 %). We observed that antiHBc antibody seropositivity does not have a significant impact on treatment responses to interferon/ribavirin therapy in patients for chronic HCV infection in contrast to some reports in the literature (Tab. 6, Ref. 39) Full Text (Free, PDF) www.bmj.sk.
Department of Gastroenterology, Ankara Education and Research Hospital, Ankara, Turkey.
Ibrahim
I
Biyikoglu
Levent
L
Filik
Dilek
D
Oguz
Bahattin
B
Cicek
Birhan
B
Yilmaz
Emin
E
Altiparmak
D000998:Antiviral Agents / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D006510:Hepatitis B Antibodies / Q000097:blood*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage*
D000998:Antiviral Agents; D006510:Hepatitis B Antibodies; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin